Sign In
Buy KLDO
$0.0001
+0 (+0%)
At Close: Jun 03, 2026
Kaleido Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results
07:35am, Wednesday, 03'rd Mar 2021
Topline data from two ongoing COVID-19 studies with KB109 expected in Q1 2021
Kaleido Biosciences to Present at Chardan's 3rd Annual Microbiome Medicines Summit
07:30am, Monday, 01'st Mar 2021
LEXINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the mic
Kaleido Biosciences (KLDO) Sees Hammer Chart Pattern: Time to Buy?
07:35am, Wednesday, 24'th Feb 2021
Kaleido Biosciences (KLDO) has been struggling lately, but the selling pressure may be coming to an end soon.
Kaleido Biosciences Announces the Exercise of the Underwriters' Option to Purchase Additional Shares of Common Stock
01:11pm, Thursday, 11'th Feb 2021
LEXINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micr
Kaleido Biosciences Announces Pricing of Public Offering of Common Stock
10:03pm, Wednesday, 03'rd Feb 2021
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micr
Kaleido Biosciences Announces Proposed Public Offering of Common Stock
04:10pm, Wednesday, 03'rd Feb 2021
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micr
Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” Conference
07:30am, Wednesday, 20'th Jan 2021
LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone Sy
Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19
07:30am, Thursday, 14'th Jan 2021
Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities
Kaleido Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
07:30am, Tuesday, 05'th Jan 2021
LEXINGTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc., (Nasdaq: KLDO) today announced that Dan Menichella, Chief Executive Officer, will present at the 39th Annual J.P. Morgan
Topline data for two studies of KB109 are expected in the first quarter of 2021 Topline data for two studies of KB109 are expected in the first quarter of 2021
Kaleido Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
07:35am, Monday, 02'nd Nov 2020
- Topline Data for KB109 for the Treatment of Mild-to-Moderate COVID-19 Expected in the First Quarter of 202 1 -
Mice Model Market Research Report 2020 - Global Forecast to 2025 & Cumulative Impact of COVID-19 - ResearchAndMarkets.com
12:00am, Thursday, 22'nd Oct 2020
The
Healthcare: XLV Survey For October (NYSEARCA:XLV)
07:46pm, Sunday, 18'th Oct 2020
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month.
Vivo Energy unveils ‘fuel the feeling’ campaign
04:45pm, Wednesday, 14'th Oct 2020
Kampala, Uganda |THE INDEPENDENT | Julius Businge | On Oct.12, fuel distributor, Vivo Energy Uganda announced a three-month nationwide campaign for motorists who use Shell V-Power, a premium fue
Medical Marijuana Market| Increasing Production of Medical Marijuana to Boost the Market Growth | Technavio
12:00am, Thursday, 08'th Oct 2020
The Global Medical Marijuana Market will grow by USD 22.33 bn during 2020-2024
